IL-1 receptor antagonist: etiological and drug delivery systems overview

Inflamm Res. 2024 Dec;73(12):2231-2247. doi: 10.1007/s00011-024-01960-y. Epub 2024 Oct 26.

Abstract

Objective: This article is aims to provide an overview of studies reported in the literature to investigate the etiological role of IL-1/IL-1ra in various disease conditions and the different drug delivery systems developed to achieve IL-1ra as a possible therapeutic option.

Methods: Studies reported in PubMed, Google scholar, and other open-source literature related to etiological involvement of IL-1ra in pathophysiological conditions and various drug delivery schemes developed for IL-1ra for its efficacy evaluation as a possible treatment for different disease conditions were surveyed.

Results and conclusions: The pathophysiological conditions involving IL-1/IL-1 ra spanned CNS-related disorders, Diabetes, Cardiac disorders, Ocular disease conditions, Gastrointestinal conditions, Tumor growth & metastasis, and miscellaneous conditions. The drug delivery systems developed for IL-1ra included a commercial drug product, Gene therapy, Antibody fusions, Extended-release delivery systems, and Pegylated-IL-1ra systems.

Keywords: Drug delivery; Etiology; Interleukin-1; Interleukin-1 receptor antagonist.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Delivery Systems*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein* / administration & dosage
  • Interleukin 1 Receptor Antagonist Protein* / therapeutic use

Substances

  • Interleukin 1 Receptor Antagonist Protein